1 / 29

Quality Standards for Melanoma 11 th October 2012

Quality Standards for Melanoma 11 th October 2012. James Larkin FRCP PhD Royal Marsden Hospital / Consultant Medical Oncologist Institute of Cancer Research London. Overview What are quality standards? How does this fit in to NICE? The Melanoma Taskforce

ziya
Download Presentation

Quality Standards for Melanoma 11 th October 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Quality Standards for Melanoma11th October 2012 James Larkin FRCP PhD Royal Marsden Hospital / Consultant Medical Oncologist Institute of Cancer Research London

  2. Overview • What are quality standards? • How does this fit in to NICE? • The Melanoma Taskforce • Melanoma Pathway Expert Working Group • Quality statements • Conclusions and next steps

  3. What are quality standards? • ‘NICE quality standards are a concise set of statements designed to drive and measure priority quality improvements within a particular area of care’ • Evidence-based; NHS and social care • 22 at present; 19 in development • E.g. breast , colorectal, lung, ovarian cancer; hip fracture, COPD, glaucoma, heart failure • 100+ are in ‘topic library’ for future development http://www.nice.org.uk/aboutnice/qualitystandards/qualitystandards.jsp

  4. Purpose of NICE quality standards • Patients, carers and the public can use NICE quality standards to provide information about the quality of care they should expect • Health and social care professionals and public health practitioners can use the quality standards in clinical audit and governance reports or in professional development and validation • Provider organisations can use the quality standards to provide high quality services for patient care and monitor quality improvements or to show successful performance in a national audit or inspection • Commissioners may use the quality standards to ensure that high quality care is being commissioned through the contracting process or to incentivise provider performance by using the indicators in association with incentive payments such as Commissioning for Quality Improvement (CQUIN) http://www.nice.org.uk/guidance/qualitystandards/moreinfoaboutnicequalitystandards.jsp

  5. Purpose of NICE quality standards Patients, carers and the public can use NICE quality standards to provide information about the quality of care they should expect Health and social care professionals and public health practitioners can use the quality standards in clinical audit and governance reports or in professional development and validation Provider organisations can use the quality standards to provide high quality services for patient care and monitor quality improvements or to show successful performance in a national audit or inspection Commissioners may use the quality standards to ensure that high quality care is being commissioned through the contracting process or to incentivise provider performance by using the indicators in association with incentive payments such as Commissioning for Quality Improvement (CQUIN) http://www.nice.org.uk/guidance/qualitystandards/moreinfoaboutnicequalitystandards.jsp

  6. Cancer quality standards • Breast cancer (P) • Colorectal cancer (P) • Lung cancer (P) • Ovarian cancer (P) • Prostate cancer • Cancer chemotherapy • Haematological malignancies • Head and neck cancer • Sarcoma • Skin cancer (including melanoma) • Children and young people with cancer • Metastatic spinal cord compression • Referral for suspected cancer • Radiotherapy services • Bladder Cancer Published In ‘topic library’ http://www.nice.org.uk/aboutnice/qualitystandards/qualitystandards.jsp

  7. Other types of NICE guidance Clinical guidelines Guidance on the appropriate treatment and care of people with specific diseases and conditions. Public health guidance NICE public health guidance makes recommendations to the NHS local authorities and other organisations in the public, private, voluntary and community sectors on how to improve people's health and prevent illness and disease. Technology appraisal guidance NICE technology appraisal guidance makes recommendations on when and how new and existing medicines and treatments should be used in the NHS. Interventional procedures guidance NICE interventional procedures guidance advises the NHS on whether new interventional procedures are safe and effective enough to be used routinely. Medical technologies guidance NICE Medical technologies guidance is designed to help the NHS adopt efficient and cost effective medical devices and diagnostics more rapidly and consistently. Diagnostic guidance NICE diagnostic guidance makes recommendations to the NHS on the efficacy and cost effectiveness of new diagnostic technologies. Cancer service guidance NICE cancer service guidance supports the implementation of The NHS Cancer Plan for England, and the NHS Plan for Wales Improving Health in Wales. Quality standards NICE Quality standards define the standard of healthcare that people can expect by indicating when a clinical treatment (or a set of clinical procedures) is highly effective cost effective and safe, and is viewed a a positive experience by patients http://www.nice.org.uk/guidance/index.jsp?action=byTopic&o=7165

  8. Other types of NICE guidance Clinical guidelines Guidance on the appropriate treatment and care of people with specific diseases and conditions. Public health guidance NICE public health guidance makes recommendations to the NHS local authorities and other organisations in the public, private, voluntary and community sectors on how to improve people's health and prevent illness and disease. Technology appraisal guidance NICE technology appraisal guidance makes recommendations on when and how new and existing medicines and treatments should be used in the NHS. Interventional procedures guidance NICE interventional procedures guidance advises the NHS on whether new interventional procedures are safe and effective enough to be used routinely. Medical technologies guidance NICE Medical technologies guidance is designed to help the NHS adopt efficient and cost effective medical devices and diagnostics more rapidly and consistently. Diagnostic guidance NICE diagnostic guidance makes recommendations to the NHS on the efficacy and cost effectiveness of new diagnostic technologies. Cancer service guidance NICE cancer service guidance supports the implementation of The NHS Cancer Plan for England, and the NHS Plan for Wales Improving Health in Wales. Quality standards NICE Quality standards define the standard of healthcare that people can expect by indicating when a clinical treatment (or a set of clinical procedures) is highly effective cost effective and safe, and is viewed a a positive experience by patients http://www.nice.org.uk/guidance/index.jsp?action=byTopic&o=7165

  9. What about clinical guidelines? • 159 clinical guidelines on diverse topics including breast, lung, colorectal, prostate and ovarian cancers • 61 in development including bladder cancer and melanoma (projected publication date June 2015) • Lung cancer clinical guideline is 200 pages long! • No planned guidance on oesophageal, stomach, pancreatic cancers or NHL (consider incidence and mortality) • Hopefully melanoma quality standard will be developed alongside melanoma clinical guideline

  10. The Melanoma Taskforce

  11. The Melanoma Taskforce

  12. The Melanoma Taskforce ‘Quality in Melanoma Care’ commissioned late in 2011

  13. Melanoma Pathway ExpertWorking Group • Simon Davies, Chief Executive Teenage Cancer Trust and Chair, Cancer52 • Stephen Kownacki, Executive Chair, PCDS • Charlotte Fionda, Development Director, Skcin • Paul Lorigan, Medical Oncologist • Jerry Marsden, Dermatologist and Chair, MSG • Julia Newton-Bishop, Dermatologist and Chair, Skin Site Specific Clinical Reference Group, NCIN • Gill Nuttall, Founder Factor50 • Veronique Poirier, Principal Cancer Intelligence Analyst, SWPHO • Barry Powell, Plastic Surgeon and National Clinical Advisor in Skin Cancer • Saskia Reeken, Skin Cancer CNS and Chair, BDNG • Daffyd Roberts, Dermatologist • Neil Shroff, GPwSI Skin Cancer, Committee Member PCDS • Meirion Thomas, Surgical Oncologist • Jacky Turner, Principal Oncology Pharmacist, GSTT • Catherine Wheelhouse, Skin Cancer CNS and Chair, British Association of Skin Cancer Specialist Nurses

  14. Melanoma Pathway ExpertWorking Group • Simon Davies, Chief Executive Teenage Cancer Trust and Chair, Cancer52 • Stephen Kownacki, Executive Chair, PCDS • Charlotte Fionda, Development Director, Skcin • Paul Lorigan, Medical Oncologist • Jerry Marsden, Dermatologist and Chair, MSG • Julia Newton-Bishop, Dermatologist and Chair, Skin Site Specific Clinical Reference Group, NCIN • Gill Nuttall, Founder Factor50 • Veronique Poirier, Principal Cancer Intelligence Analyst, SWPHO • Barry Powell, Plastic Surgeon and National Clinical Advisor in Skin Cancer • Saskia Reeken, Skin Cancer CNS and Chair, BDNG • Daffyd Roberts, Dermatologist • Neil Shroff, GPwSI Skin Cancer, Committee Member PCDS • Meirion Thomas, Surgical Oncologist • Jacky Turner, Principal Oncology Pharmacist, GSTT • Catherine Wheelhouse, Skin Cancer CNS and Chair, British Association of Skin Cancer Specialist Nurses Multidisciplinary and geographically representative

  15. Melanoma Pathway ExpertWorking Group: Process • Meetings in February and May 2012 • Other work outside meetings • 5 core teams (primary care, dermatology, surgery, oncology and survivorship/end of life care) • Cross-cutting group reviewed work of teams • Developed 16 quality statements and other recommendations; they describe the…

  16. Quality Statements

  17. Quality Statements

  18. Quality Statements

  19. Quality Statements

  20. Conclusions and next steps Positive that clinical guideline and quality standard planned for melanoma Hopefully the quality statements we have developed will be taken into account by the group working on these Whether there is any scope for this to inform quality of care before 2015 is unclear There may be disagreement about some of the statements but unity as a community is vital Comments and suggestions gratefully received

  21. Acknowledgements Sian James MP Expert Working Group Secretariat, particularly Daniel Cambers and Katie Russell

  22. Thank you

  23. How are quality standards developed? http://www.nice.org.uk/guidance/qualitystandards/moreinfoaboutnicequalitystandards.jsp#How are topics selected?

  24. How are quality standards developed? http://www.nice.org.uk/guidance/qualitystandards/moreinfoaboutnicequalitystandards.jsp#How are topics selected?

  25. Expert Recommendations

  26. Expert Recommendations

  27. Expert Recommendations

  28. Expert Recommendations

  29. Expert Recommendations

More Related